Did you know?

On November 14, 2022, the Food and Drug Administration granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc.) for adult patients with folate receptor alpha (FRα ...Nov 20, 2023 · ImmunoGen, Inc. is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Nov 30, 2023 · Shares of Waltham, Massachusetts.-based ImmunoGen Inc. soared more than 80% to top $29 in mid-morning trading Thursday. North Chicago, Illinois-based AbbVie Inc. stock was up 2% to $141.26 while ... ImmunoGen will release figures for the most recent quarter on November 2. Forecasts of 13 analysts expect earnings of $0.044 per share compared to losses of $0.310 per share from the same quarter ...Get the latest ImmunoGen, Inc. (IMGN) real-time quote, historical performance, charts, and other financial information to help you make more informed ...AbbVie (ABBV) is set to acquire Immunogen (IMGN) for $10 billion in cash, to access a new cancer drug class called antibody-drug conjugates (ADC). Read more here.The FDA granted accelerated approval for ImmunoGen Inc's (NASDAQ:IMGN) Elahere (mirvetuximab soravtansine-gynx) for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian ...May 3, 2023 · WALTHAM, Mass., May 03, 2023 -- ( BUSINESS WIRE )-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced ... Name. Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a ...Get the latest news and real-time alerts from ImmunoGen, Inc. (IMGN) stock at Seeking Alpha.4 days ago ... For ImmunoGen, AbbVie will pay $31.26 per share in cash, representing a ... News; AbbVie signs $10 bln deal to buy cancer drugmaker ImmunoGen.Shares of Waltham, Massachusetts.-based ImmunoGen Inc. soared more than 80% to top $29 in mid-morning trading Thursday. North Chicago, Illinois-based AbbVie Inc. stock was up 2% to $141.26 while ...Shares of ImmunoGen jumped more than 80% on Thursday, putting it on track for its highest close since November 2000. Meanwhile, AbbVie's stock rose more than 2%. Meanwhile, AbbVie's stock rose ...What's going on at ImmunoGen (NASDAQ:IMGN)? Read today's IMGN news from trusted media outlets at MarketBeat.40 years ago, ImmunoGen began as an idea. Baruj Benacerraf, head of the Sidney Farber Cancer Institute (now the Dana Farber Cancer Institute), was approached by a small …The FDA granted accelerated approval for ImmunoGen Inc's (NASDAQ:IMGN) Elahere (mirvetuximab soravtansine-gynx) for folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian ...Nov 30, 2023 · AbbVie and ImmunoGen said Thursday that the boards of both companies have approved the transaction. It’s expected to close in the middle of 2024. It still needs approval from ImmunoGen shareholders and regulators. Shares of Waltham, Massachusetts.-based ImmunoGen Inc. soared more than 80% to top $29 in mid-morning trading Thursday. Get the latest ImmunoGen, Inc. (IMGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.AbbVie bets $10 billion on ImmunoGen to boost its oncology portfolio. 30-11-2023. Shares of US antibody-drug conjugate (ADC) specialist ImmunoGen shot up more that 83% to $29.46 pre-market today, on the news of a definitive agreement to be acquired by pharma major AbbVie.Jun 9, 2023 · WALTHAM, Mass., June 09, 2023--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced updated data from an ... Nov 30, 2023 · The need-to-know this morning. • Abbvie said it would acquire ImmunoGen, a maker of cancer drugs, for $10.1 billion. ImmunoGen is being acquired for $31.26 per share, or a 95% premium to its ... Get the latest ImmunoGen, Inc. (IMGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Prior to yesterday's news, ImmunoGen stock had been trading at a value of ~$4 - which is about the average across the past 5 year period. Shares ended the day trading at $12.2 - their highest ...ImmunoGen ( NASDAQ: IMGN) jumped 12% on speculatioImmunoGen shares gained 82.8% to close at $29.35 on Shares of ImmunoGen jumped more than 80% on Thursday, putting it on track for its highest close since November 2000. Meanwhile, AbbVie's stock rose more than 2%. Meanwhile, AbbVie's stock rose ... View the latest Immunogen Inc. (IMGN) stock price, news, histor 1 day ago · ImmunoGen lost $21 million from operation through Q3 2023, as depicted below. ImmunoGen 10-Q The company spent a whopping $114 million on selling, general, and administrative costs (SG&A). May 3, 2023 · Reuters. May 3 (Reuters) - ImmunoGen Inc (IMGN.O) shares more than doubled on Wednesday after the company said its experimental ovarian cancer drug helped extend the lives of patients in a late ... Find people you know at ImmunoGen, Inc. Browse recommende

WALTHAM, Mass., May 03, 2023 -- ( BUSINESS WIRE )-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced ...AbbVie Inc. (NYSE: ABBV) will spend about $10.1 billion to acquire ImmunoGen Inc. (Nasdaq: IMGN), the companies announced Thursday. The deal …Find real-time IMGN - ImmunoGen Inc stock quotes, company profile, news and forecasts from CNN Business. View the latest Immunogen Inc. (IMGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review.July 31, 2023 at 3:35 AM · 3 min read. WALTHAM, Mass., July 31, 2023 -- ( BUSINESS WIRE )-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. 5 days ago ... Endpoints News. Bioscience &a. Possible cause: Big news for ImmunoGen! I was there in 2000 when the stock last traded in the 30's as .